| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $472,136 | 10 | 83 |
Sells | $39,190 | 2 | 17 |
| Polymeropoulos Mihael Hristos | President and CEO | 9 | $463,357 | 0 | $0 | $463,357 |
| Moran Kevin Patrick | SVP, CFO & Treasurer | 1 | $8,779 | 1 | $13,327 | $-4,548 |
| Mitchell Stephen Ray | director | 0 | $0 | 1 | $25,863 | $-25,863 |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Over the last 12 months, insiders at Vanda Pharmaceuticals Inc. have bought $472,136 and sold $39,190 worth of Vanda Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Vanda Pharmaceuticals Inc. have bought $472,136 and sold $2.8M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Polymeropoulos Mihael Hristos (President and CEO) — $463,357. Moran Kevin Patrick (SVP, CFO & Treasurer) — $8,779.
The last purchase of 10,000 shares for transaction amount of $43,995 was made by Polymeropoulos Mihael Hristos (President and CEO) on 2025‑05‑21.
| 2025-05-21 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0173% | $4.40 | $43,995 | -0.40% | ||
| 2025-05-16 | Polymeropoulos Mihael Hristos | President and CEO | 20,000 0.0345% | $4.22 | $84,472 | +9.06% | ||
| 2025-03-06 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0176% | $5.01 | $50,150 | -10.49% | ||
| 2025-03-05 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0169% | $5.02 | $50,200 | -14.23% | ||
| 2025-03-03 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0172% | $4.71 | $47,050 | -6.62% | ||
| 2025-02-28 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0171% | $4.76 | $47,600 | -7.35% | ||
| 2025-02-27 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0172% | $4.76 | $47,600 | -5.96% | ||
| 2025-02-26 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0174% | $4.76 | $47,650 | -5.94% | ||
| 2025-02-25 | Polymeropoulos Mihael Hristos | President and CEO | 10,000 0.0173% | $4.46 | $44,640 | -0.62% | ||
| 2025-02-21 | Moran Kevin Patrick | SVP, CFO & Treasurer | 2,000 0.0034% | $4.39 | $8,779 | +0.06% | ||
| 2024-11-14 | Sale | Mitchell Stephen Ray | director | 5,000 0.0086% | $5.17 | $25,863 | -10.00% | |
| 2024-07-29 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 2,251 0.0038% | $5.92 | $13,327 | -21.83% | |
| 2024-03-05 | Sale | Polymeropoulos Mihael Hristos | President and CEO | 24,288 0.0421% | $4.13 | $100,273 | +17.15% | |
| 2024-03-05 | Sale | Birznieks Gunther | SVP, Business Development | 8,684 0.0151% | $4.13 | $35,884 | +17.15% | |
| 2024-03-05 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 8,902 0.0157% | $4.20 | $37,411 | +17.15% | |
| 2024-03-05 | Sale | Williams Timothy | SVP & General Counsel | 8,941 0.0157% | $4.18 | $37,396 | +17.15% | |
| 2024-03-05 | Sale | Wijkstrom Joakim | SVP, Chief Marketing Officer | 9,229 0.0163% | $4.21 | $38,830 | +17.15% | |
| 2024-03-04 | Sale | Polymeropoulos Mihael Hristos | President and CEO | 30,884 0.0534% | $4.24 | $131,066 | +13.47% | |
| 2024-03-04 | Sale | Birznieks Gunther | SVP, Business Development | 8,727 0.0153% | $4.30 | $37,495 | +13.47% | |
| 2024-03-04 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 5,798 0.0106% | $4.48 | $25,982 | +13.47% |
| Polymeropoulos Mihael Hristos | President and CEO | 2325731 3.9463% | $10.49M | 14 | 52 | <0.0001% |
| Moran Kevin Patrick | SVP, CFO & Treasurer | 355763 0.6037% | $1.6M | 1 | 14 | |
| Mitchell Stephen Ray | director | 44857 0.0761% | $202,305.07 | 0 | 5 | |
| TANG KEVIN C | 10 percent owner | 2715852 4.6083% | $12.25M | 6 | 8 | |
| RHO VENTURES IV LP | 10 percent owner | 1862692 3.1606% | $8.4M | 0 | 2 | |
| Biomedical Sciences Investment Fund Pte Ltd. | 10 percent owner | 1856957 3.1509% | $8.37M | 0 | 5 | |
| Flynn James E | 10 percent owner | 693171 1.1762% | $3.13M | 5 | 5 | +15.47% |
| Birznieks Gunther | SVP, Business Development | 313569 0.5321% | $1.41M | 0 | 17 | |
| Williams Timothy | SVP & General Counsel | 196825 0.334% | $887,680.75 | 0 | 16 | |
| Kelly James Patrick | EVP & Chief Financial Officer | 186869 0.3171% | $842,779.19 | 1 | 14 | <0.0001% |
| Clark William D | Sr. VP, Chief Business Officer | 168279 0.2855% | $758,938.29 | 1 | 10 | |
| Reverberi Gian Piero | SVP & Chief Commercial Officer | 165384 0.2806% | $745,881.84 | 0 | 5 | |
| Wijkstrom Joakim | SVP, Chief Marketing Officer | 129789 0.2202% | $585,348.39 | 0 | 10 | |
| CARE CAPITAL II LLC | 10 percent owner | 121546 0.2062% | $548,172.46 | 0 | 7 | |
| Gulino Richard L. | SVP, General Counsel & Sec. | 115073 0.1953% | $518,979.23 | 0 | 3 | |
| Jones Aranthan II | Chief Corp. Affairs Officer | 81980 0.1391% | $369,729.80 | 0 | 7 | |
| DUGAN RICHARD W | 68387 0.116% | $308,425.37 | 0 | 5 | ||
| Watkins Thomas | 63064 0.107% | $284,418.64 | 0 | 4 | ||
| Baroldi Paolo | SVP & Chief Medical Officer | 54365 0.0922% | $245,186.15 | 0 | 3 | |
| TREU JESSE I | 10 percent owner | 21068 0.0357% | $95,016.68 | 0 | 1 | |
| BLAIR JAMES C | director | 21068 0.0357% | $95,016.68 | 0 | 1 | |
| VITULLO NICOLE | 10 percent owner | 21068 0.0357% | $95,016.68 | 0 | 1 | |
| DOVEY BRIAN H | 10 percent owner | 21068 0.0357% | $95,016.68 | 0 | 1 | |
| SCHOEMAKER KATHLEEN K | 10 percent owner | 21068 0.0357% | $95,016.68 | 0 | 1 | |
| MORE ROBERT J | 10 percent owner | 21068 0.0357% | $95,016.68 | 0 | 1 | |
| DP VI Associates, L.P. | 10 percent owner | 21068 0.0357% | $95,016.68 | 0 | 1 | |
| Repella Robert | SVP & Chief Commercial Officer | 15000 0.0255% | $67,650.00 | 0 | 3 | |
| Chrousos Phaedra | director | 12925 0.0219% | $58,291.75 | 0 | 1 | |
| Feeney John Joseph | SVP & Chief Medical Officer | 11942 0.0203% | $53,858.42 | 0 | 8 | |
| TANANBAUM JAMES B | director | 11041 0.0187% | $49,794.91 | 0 | 2 | |
| Irish Stephanie Rast | Acting CFO/Treasurer | 2249 0.0038% | $10,142.99 | 0 | 3 | |
| KARABELAS ARGERIS N | director | 0 0% | $0 | 0 | 19 | |
| SHALLCROSS STEVEN A | Sr. VP, CFO, Treasurer | 0 0% | $0 | 0 | 13 | |
| Ramsay David Russ | 0 0% | $0 | 0 | 19 | ||
| Phadke Deepak Shripad | Vice President Manufacturing | 0 0% | $0 | 0 | 1 |
$860,541,348 | 82 | -5.10% | $243.87M | |
$69,130,029 | 69 | 25.63% | $285.41M | |
$17,983,739 | 41 | 102.87% | $253.46M | |
$109,415,500 | 33 | 18.13% | $294.45M | |
$144,247,213 | 29 | 10.15% | $257.6M | |
$73,500,193 | 28 | 42.95% | $288.07M | |
$14,865,077 | 18 | -28.56% | $257.03M | |
$3,232,510 | 15 | -2.42% | $281.85M | |
$109,488,423 | 15 | 56.69% | $273.44M | |
$57,263,116 | 11 | -8.37% | $293.1M | |
$133,369,382 | 10 | 5.02% | $285.32M | |
$58,981,940 | 10 | 32.58% | $273.19M | |
$55,069,530 | 9 | 25.25% | $245.37M | |
Vanda Pharmaceuticals Inc. (VNDA) | $14,995,689 | 8 | 3.76% | $265.79M |
$58,352 | 4 | -43.78% | $248.83M | |
$4,888,000 | 3 | -20.50% | $240.8M | |
$879,499 | 1 | 28.50% | $245.04M | |
$63,731 | 1 | -19.50% | $253.68M | |
$102,796 | 1 | -21.40% | $270.43M |
| Increased Positions | 66 | +38.37% | 4M | +10.38% |
| Decreased Positions | 71 | -41.28% | 4M | -8.12% |
| New Positions | 22 | New | 980,246 | New |
| Sold Out Positions | 18 | Sold Out | 569,159 | Sold Out |
| Total Postitions | 167 | -2.91% | 44M | +2.26% |
| Blackrock, Inc. | $41,724.00 | 15.47% | 9.13M | +25,717 | +0.28% | 2025-03-31 |
| Renaissance Technologies Llc | $17,612.00 | 6.53% | 3.85M | -157,723 | -3.93% | 2024-12-31 |
| Vanguard Group Inc | $16,024.00 | 5.94% | 3.51M | -125,002 | -3.44% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $11,373.00 | 4.22% | 2.49M | +227,428 | +10.06% | 2024-12-31 |
| Tang Capital Management Llc | $10,755.00 | 3.99% | 2.35M | 0 | 0% | 2024-12-31 |
| Acadian Asset Management Llc | $8,683.00 | 3.22% | 1.9M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $6,628.00 | 2.46% | 1.45M | +24,483 | +1.72% | 2024-12-31 |
| Morgan Stanley | $6,126.00 | 2.27% | 1.34M | +724,082 | +117.47% | 2024-12-31 |
| State Street Corp | $5,410.00 | 2.01% | 1.18M | +18,681 | +1.6% | 2024-12-31 |
| Schroder Investment Management Group | $4,744.00 | 1.76% | 1.04M | 0 | 0% | 2024-12-31 |